Xeris Biopharma Holdings, Inc. reported fourth‑quarter 2025 revenue of $85.8 million, up 43% from $49.6 million a year earlier, and a net income of $11.1 million, a turnaround from a $5.1 million loss in the same period last year. The company’s basic earnings per share of $0.06 beat the consensus estimate of $0.03 by $0.03, a 100% surprise that reflects disciplined cost control and strong product mix. Full‑year 2025 revenue reached $292 million, up 44% from $191 million in 2024, and net income of $0.6 million, compared with a $54.8 million loss in 2024.
Recorlev, Xeris’s flagship drug for Cushing’s syndrome, generated $45.3 million in product revenue in Q4, a 100% year‑over‑year increase that underscores robust demand and pricing power. Gvoke, the severe hypoglycemia treatment, contributed $24.6 million, while Keveyis, a therapy for primary periodic paralysis, added $12.8 million. Royalty, contract and other revenue fell 23% to $2.4 million, a decline driven by reduced licensing activity in the quarter. Adjusted EBITDA rose to $25.1 million, an improvement of $16.8 million over Q4 2024, driven by higher product sales and margin expansion in the core portfolio.
Gross margin for the quarter was 87%, up from 85% in the prior year, reflecting a favorable mix of high‑margin products and efficient manufacturing. The company’s operating leverage is evident in the jump in adjusted EBITDA, which grew by $16.8 million from the previous year’s $8.3 million. These gains are supported by continued scale in Recorlev sales and disciplined cost management across the organization.
Management guided 2026 total revenue to $375 million–$390 million, a midpoint that represents more than 30% growth from the 2025 year. CEO John Shannon said, “Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self‑funding, sustainable biopharmaceutical company.” CFO Steve Pieper added, “Our exceptional results in 2025 reflect the strength of our business and set the stage for our future. As we look ahead to 2026, we will build on the strong momentum across our enterprise and expect total revenue to range from approximately $375 million to $390 million, representing more than 30% growth at the midpoint.” The guidance signals confidence in continued demand for the commercial portfolio and the launch of the XP‑8121 Phase 3 program.
Analysts reacted positively to the earnings beat, noting that the company’s revenue and EPS outperformance, combined with a robust guidance range, reinforced its self‑funding narrative. The market welcomed the strong performance of Recorlev, the largest contributor to revenue growth, and the company’s plan to step up R&D investment for XP‑8121, which management believes could become a $1 billion–$3 billion blockbuster. The guidance also reflects a strategic shift toward disciplined capital deployment to support both commercial expansion and pipeline development.
Xeris’s transition to profitability and its ability to fund growth internally marks a significant milestone in its evolution from a high‑cost, high‑risk biotech to a sustainable biopharmaceutical company. The company’s focus on scaling Recorlev, expanding Gvoke and Keveyis, and advancing XP‑8121 positions it to capture a larger share of the specialty‑drug market while maintaining a strong balance sheet. The forward guidance, coupled with the company’s self‑funding status, suggests a resilient business model that can weather competitive pressures and continue to deliver shareholder value over the long term.
The company’s performance demonstrates that disciplined execution, a strong product mix, and strategic investment in pipeline assets can transform a high‑loss biotech into a profitable, self‑sustaining enterprise. Investors will likely view the earnings beat and robust guidance as a signal of continued growth potential and operational excellence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.